Nana Takagi

Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.

Satoshi Nakamura, T. Mikkaichi, H. Maeda, 2013, Journal of pharmacological sciences.

Identification of the 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivatives as highly selective PDE4B inhibitors.

Mizuki Takahashi, S. Sasaki, T. Mikkaichi, 2014, Bioorganic & medicinal chemistry letters.

Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.

N. Udagawa, N. Amizuka, S. Kumakura, 2021, Bone.

Renadirsen, a Novel 2′OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo

Y. Takeshima, M. Matsuo, M. Koizumi, 2021, Current issues in molecular biology.

RS-1748, a novel CC chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs.

M. Yamashita, T. Fukuda, Y. Nakagami, 2010, Biological & pharmaceutical bulletin.

CorrigendumCorrigendum to “Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: Analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog” [Biochem. Pharmacol. 77 (2009) 1011–1020]

Tatsuya Inoue, S. Kumakura, Y. Takuwa, 2010 .

Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of non-sphingosine-1-phosphate analog.

Tatsuya Inoue, S. Kumakura, Y. Takuwa, 2009, Biochemical pharmacology.